---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-016838"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T12:05:46.564282+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCardia Q1 2025 net loss $2.7M; CardiAMP HF two-year data shows survival benefit; Helix FDA submission planned

## Summary
- Two-year results from Phase 3 CardiAMP HF trial (presented Mar 30) showed increased survival, fewer CV events, improved QoL; significant in NTproBNP-elevated subset (p=0.02).
- CardiAMP HF II confirmatory trial underway with three active sites; primary endpoint based on hierarchical analysis.
- Refractory angina roll-in cohort showed 107 sec increase in exercise tolerance and 82% reduction in angina episodes at 6 months.
- R&D expenses $1.5M, SG&A $1.2M; net loss $2.7M vs $2.3M YoY; cash used in ops $1.6M.
- Plans to submit CardiAMP Cell Therapy for Japan PMDA consultation and Helix delivery system for FDA approval this quarter.

## SEC filing metadata
- accession: 0001437749-25-016838
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925016838/0001437749-25-016838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925016838/bcda20250513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-016838
- JSON: https://secwatch.observer/filing/0001437749-25-016838.json
- Plain text: https://secwatch.observer/filing/0001437749-25-016838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.